Welcome to the UPF Digital Repository

Browsing by Author "Alzheimer’s Disease Neuroimaging Initiative"

Browsing by Author "Alzheimer’s Disease Neuroimaging Initiative"

Sort by: Order: Results:

  • Cacciaglia, Raffaele; Salvadó, Gemma; Molinuevo, José Luis; Shekari, Mahnaz; Falcón, Carles; Operto, Grégory; Suárez-Calvet, Marc; Milà Alomà, Marta; Sala, Arianna; Rodriguez-Vieitez, Elena; Kollmorgen, Gwendlyn; Suridjan, Ivonne; Blennow, Kaj; Zetterberg, Henrik; Gispert López, Juan Domingo; Alzheimer’s Disease Neuroimaging Initiative; ALFA Study (Nature Research, 2022)
    Amyloid (Aβ) pathology is the earliest detectable pathophysiological event along the Alzheimer's continuum, which can be measured both in the cerebrospinal fluid (CSF) and by Positron Emission Tomography (PET). Yet, these ...
  • Zettergren, Anna; Lord, Jodie; Ashton, Nicholas J.; Benedet, Andrea L.; Karikari, Thomas K.; Lantero Rodriguez, Juan; Alzheimer’s Disease Neuroimaging Initiative; Snellman, Anniina; Suárez-Calvet, Marc; Proitsi, Petroula; Zetterberg, Henrik; Blennow, Kaj (BioMed Central, 2021)
    Background: Recent studies suggest that plasma phosphorylated tau181 (p-tau181) is a highly specific biomarker for Alzheimer's disease (AD)-related tau pathology. It has great potential for the diagnostic and prognostic ...
  • Salvadó, Gemma; Molinuevo, José Luis; Brugulat Serrat, Anna, 1986-; Falcón, Carles; Grau-Rivera, Oriol; Suárez-Calvet, Marc; Pavía Segura, Javier; Niñerola-Baizán, Aida; Perissinotti, Andrés; Lomeña, Francisco; Minguillón, Carolina; Fauria, Karine; Zetterberg, Henrik; Blennow, Kaj; Gispert López, Juan Domingo; Alzheimer’s Disease Neuroimaging Initiative (BioMed Central, 2019)
    Background: The Centiloid scale has been developed to standardize measurements of amyloid PET imaging. Reference cut-off values of this continuous measurement enable the consistent operationalization of decision-making for ...
  • Karikari, Thomas K.; Benedet, Andrea L.; Ashton, Nicholas J.; Lantero Rodríguez, Juan; Snellman, Anniina; Suárez-Calvet, Marc; Saha-Chaudhuri, Paramita; Lussier, Firoza; Kvartsberg, Hlin; Moscoso Rial, Alexis; Pascoal, Tharick A.; Andreasson, Ulf; Schöll, Michael; Weiner, Michael W.; Rosa-Neto, Pedro; Trojanowski, John Q.; Shaw, Leslie M.; Blennow, Kaj; Zetterberg, Henrik; Alzheimer’s Disease Neuroimaging Initiative (Nature Research, 2021)
    Whilst cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers for amyloid-β (Aβ) and tau pathologies are accurate for the diagnosis of Alzheimer's disease (AD), their broad implementation in clinical ...
  • Salvadó, Gemma; Grothe, Michel J.; Groot, Colin; Moscoso, Alexis; Schöll, Michael; Gispert López, Juan Domingo; Ossenkoppele, Rik; Alzheimer’s Disease Neuroimaging Initiative (Springer, 2021)
    Purpose: To examine associations between the APOE-ε2 and APOE-ε4 alleles and core Alzheimer's disease (AD) pathological hallmarks as measured by amyloid-β (Aβ) and tau PET in older individuals without dementia. Methods: ...
  • Vilor Tejedor, Natàlia, 1988-; Genius, Patricia; Rodríguez-Fernández, Blanca; Minguillón, Carolina; Sadeghi, Iman; González Escalante, Armand; Crous-Bou, Marta; Suárez-Calvet, Marc; Grau-Rivera, Oriol; Brugulat Serrat, Anna, 1986-; Sánchez Benavides, Gonzalo; Esteller, Manel; Fauria, Karine; Molinuevo, José Luis; Navarro i Cuartiellas, Arcadi, 1969-; Gispert López, Juan Domingo; Alzheimer’s Disease Neuroimaging Initiative; ALFA Study (Wiley, 2024)
    Introduction: In 2013, the ALzheimer's and FAmilies (ALFA) project was established to investigate pathophysiological changes in preclinical Alzheimer's disease (AD), and to foster research on early detection and preventive ...
  • Ewers, Michael; Biechele, Gloria; Suárez-Calvet, Marc; Sacher, Christian; Blume, Tanja; Morenas-Rodriguez, Estrella; Deming, Yuetiva; Piccio, Laura; Cruchaga, Carlos; Kleinberger, Gernot; Shaw, Leslie; Trojanowski, John Q.; Herms, Jochen; Dichgans, Martin; Alzheimer’s Disease Neuroimaging Initiative; Brendel, Matthias; Haass, Christian; Franzmeier, Nicolai (Wiley, 2020)
    Microglia activation is the brain's major immune response to amyloid plaques in Alzheimer's disease (AD). Both cerebrospinal fluid (CSF) levels of soluble TREM2 (sTREM2), a biomarker of microglia activation, and microglia ...
  • Moscoso, Alexis; Grothe, Michel J.; Ashton, Nicholas J.; Karikari, Thomas K.; Lantero Rodriguez, Juan; Snellman, Anniina; Suárez-Calvet, Marc; Blennow, Kaj; Zetterberg, Henrik; Schöll, Michael; Alzheimer’s Disease Neuroimaging Initiative (American Medical Association, 2021)
    Importance: Plasma phosphorylated tau at threonine 181 (p-tau181) has been proposed as an easily accessible biomarker for the detection of Alzheimer disease (AD) pathology, but its ability to monitor disease progression ...
  • Casamitjana, Adrià; Vilaplana, Verónica; Puch, Santi; Aduriz, Asier; López, Carlos; Operto, Grégory; Cacciaglia, Raffaele; Falcón, Carles; Molinuevo, José Luis; Domingo Gispert, Juan; Alzheimer’s Disease Neuroimaging Initiative (SpringerOpen, 2021)
    NeAT is a modular, flexible and user-friendly neuroimaging analysis toolbox for modeling linear and nonlinear effects overcoming the limitations of the standard neuroimaging methods which are solely based on linear models. ...
  • Martí Juan, Gerard; Sanromà, Gerard; Cacciaglia, Raffaele; Falcón, Carles; Operto, Grégory; Molinuevo, José Luis; González Ballester, Miguel Ángel, 1973-; Domingo Gispert, Juan; Piella Fenoy, Gemma; Alzheimer’s Disease Neuroimaging Initiative; ALFA Study (Wiley, 2020)
    The ε4 allele of the gene Apolipoprotein E is the major genetic risk factor for Alzheimer's Disease. APOE ε4 has been associated with changes in brain structure in cognitively impaired and unimpaired subjects, including ...
  • Petrone, Paula M.; Casamitjana, Adrià; Falcón, Carles; Artigues, Miquel; Operto, Grégory; Cacciaglia, Raffaele; Molinuevo, José Luis; Vilaplana, Verónica; Gispert López, Juan Domingo; Alzheimer’s Disease Neuroimaging Initiative (BioMed Central, 2019)
    Background: Magnetic resonance imaging (MRI) has unveiled specific alterations at different stages of Alzheimer's disease (AD) pathophysiologic continuum constituting what has been established as "AD signature". To what ...
  • Collij, Lyduine E.; Salvadó, Gemma; Wottschel, Viktor; Mastenbroek, Sophie E.; Schoenmakers, Pierre; Heeman, Fiona; Aksman, Leon; Wink, Alle Meije; Berckel, Bart N.M.; van de Flier, Wiesje M.; Scheltens, Philip; Visser, Pieter Jelle; Barkhof, Frederik; Haller, Sven; Gispert López, Juan Domingo; Lopes Alves, Isadora; Alzheimer’s Disease Neuroimaging Initiative; ALFA Study (Lippincott Williams & Wilkins, 2022)
    Background and objectives: β-amyloid (Aβ) staging models assume a single spatial-temporal progression of amyloid accumulation. We assessed evidence for Aβ accumulation subtypes by applying the data-driven Subtype and Stage ...
  • Biel, Davina; Suárez-Calvet, Marc; Hager, Paul; Rubinski, Annna; Dewenter Anna; Steward, Anna; Roemer, Sebastian; Ewers, Michael; Haass, Christian; Brendel, Matthias; Franzmeier, Nicolai; Alzheimer’s Disease Neuroimaging Initiative (EMBO Press, 2023)
    Microglial activation occurs early in Alzheimer's disease (AD) and previous studies reported both detrimental and protective effects of microglia on AD progression. Here, we used CSF sTREM2 to investigate disease stage‐dependent ...
  • Moscoso, Alexis; Grothe, Michel J.; Ashton, Nicholas J.; Karikari, Thomas K.; Lantero Rodriguez, Juan; Snellman, Anniina; Suárez-Calvet, Marc; Zetterberg, Henrik; Blennow, Kaj; Schöll, Michael; Alzheimer’s Disease Neuroimaging Initiative (Oxford University Press, 2021)
    Tau phosphorylated at threonine 181 (p-tau181) measured in blood plasma has recently been proposed as an accessible, scalable, and highly specific biomarker for Alzheimer's disease. Longitudinal studies, however, investigating ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking